Form 4: Champions Oncology Director Acquires Stock Options

Daniel Mendelson, a director at Champions Oncology, acquired 21,590 stock options on November 12, 2024.

Summary

• Daniel Mendelson, a director of Champions Oncology, Inc., was granted 21,590 stock options on November 12, 2024.
• The options have an exercise price of $4.64 per share.
• The options vest over a twelve-month period, with vesting dates on November 12, 2024, February 12, 2025, May 12, 2025, and August 12, 2025.
• The options expire on November 12, 2034.

Sentiment

Score: 6

Explanation: The document is a routine disclosure of a stock option grant to a director. It is neither particularly positive nor negative, but it does indicate that a director has a vested interest in the company's performance.

Positives

• The acquisition of stock options by a director can be seen as a positive sign of confidence in the company's future performance.

Industry Context

This is a standard SEC Form 4 filing, which is common for publicly traded companies when insiders make transactions in their company's securities. It is a routine disclosure and does not indicate any specific industry trend.

Comparison to Industry Standards

• Stock option grants to directors are a common practice in publicly traded companies as part of their compensation and incentive programs.
• The vesting schedule of 12 months is fairly standard for such grants.
• The exercise price of $4.64 is specific to Champions Oncology and would need to be compared to the current market price of the stock to assess its value.

Stakeholder Impact

• The stock option grant could potentially increase shareholder value if the company performs well and the options become exercisable at a profit.

Key Dates

Keywords

stock options, insider trading, director, Champions Oncology, equity, CSBR